[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"charcot-marie-tooth\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:charcot-marie-tooth":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,50,88,183,212,249],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":38,"lastUpdatePostDateStruct":39,"startDateStruct":42,"completionDateStruct":44,"leadSponsor":46,"locationsCount":49},"100617696","assessment-of-a-portable-digital-device-for-quantified-analysis-of-markerless-walking-in-volunteers-with-neuromuscular-diseases-or-asymptomatic-volunteers-100617696",false,"NCT07321977","Assessment of a Portable Digital Device for Quantified Analysis of Markerless Walking in Volunteers With Neuromuscular Diseases or Asymptomatic Volunteers","Myokinesis","* All volunteers\n\n  * Age between 18 and 65\n  * Ambulatory\n  * Informed consent to participate in the study\n  * Member of or beneficiary of a social security system\n* Volunteers with a neuromuscular disease\n\n  * Confirmed diagnosis of a neuromuscular disease of genetic origin (medical document to be provided upon enrollment in the study with proof of diagnosis) belonging to the list above.\n  * Ability to walk for 2 minutes without assistance.\n  * Ability to stand up from a chair with armrests at least 3 times in 30 seconds.\n  * Ability to climb an inclined plane independently or with assistance to access the movement analysis room.\n\nExclusion Criteria\n\n* All volunteers\n\n  * Individuals under guardianship, curatorship, or legal protection\n  * Pregnant or breastfeeding women\n  * Non-ambulatory individuals\n  * Individuals with epilepsy\n  * Skin conditions preventing the placement of VICON motion sensors\n* Asymptomatic volunteers\n\n  * Unstable respiratory or cardiac problems\n  * Neurological, musculoskeletal, or psychiatric problems\n* Volunteers with a neuromuscular disease\n\n  * Recent trauma or serious falls (≤ 6 months)\n  * Individuals who have fallen more than twice in the past year and at least once in the past three months\n  * Use of assistive devices such as rigid knee braces or walkers\n  * Unstable cardiomyopathy\n  * Individuals awaiting diagnosis\n\nExclusion criteria\n\n* Inability to comply with the protocol requirements\n* Medical or social conditions that could interfere with the study, as determined by the coordinating investigator or co-investigators.",true,"ALL","18 Years","65 Years",{"count":21,"type":22},30,"ESTIMATED","INTERVENTIONAL",[25],"NA","In recent years, knowledge of neuromuscular diseases has advanced considerably, and new therapeutic avenues are beginning to emerge. The proliferation of clinical trials has created a need to identify biomarkers that are both sensitive to changes and specific to the disease. Current gait tests only consider the time factor and not the evolution of the patient's biomechanics, which may prove insufficient for patients whose symptoms generally progress slowly. Quantifying gait parameters in neuromuscular patients therefore appears necessary. This is why we propose to study markerless gait analysis in this population, which would allow for simple and effective monitoring of kinematic parameters without resorting to complex equipment incompatible with routine clinical practice.",[28,29,30,31],"Spinal Muscular Atrophy (SMA)","Charcot-Marie-Tooth","Muscular Dystrophy","Myotonic Dystrophy",[33,34,35,36],"gait analysis","neuromuscular","disease","markerless","RECRUITING","2026-05-18",{"date":40,"type":41},"2026-05-19","ACTUAL",{"date":43,"type":41},"2026-03-03",{"date":45,"type":22},"2027-01-06",{"name":47,"class":48},"Institut de Myologie, France","OTHER",1,{"id":51,"slug":52,"hasResults":11,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":67,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":49},"100628458","studying-nerve-function-and-structure-in-charcot-marie-tooth-disease-anti-mag-neuropathy-and-cidp-100628458","NCT07461896","Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP","Axonal Excitability and Ultrasound Patterns in Charcot-Marie-Tooth Disease and Other Demyelinating Disorders","CMT-NFS","Inclusion Criteria:\n\n1. The subject is ≥ 18 years old.\n\n   AND:\n2. A genetically confirmed diagnosis of one of the several CMT subtypes (i.e., CMT1A, CMT1B, CMTX1, CMT2I\u002FJ, CMT4B, CMT4D and CMT4J) OR\n3. A clinical diagnosis of either Chronic Inflammatory Demyelinating Polyneuropathy or anti-MAG polyneuropathy\n\nExclusion Criteria:\n\n1. Known neuropathy from another cause (e.g., diabetes, chronic renal insufficiency, medications, alcohol), including previous carpal tunnel syndrome surgery.\n2. History of exposure to chemotherapeutic agents (e.g., bortezomib, vincristine, cisplatin, taxol, vedotin\u002Fauromycin-conjugated antibodies), or other medications (e.g., disulfuram, thalidomide, voriconizole, chronic colchicine use) that can cause neuropathy, active alcohol abuse.\n3. History of cancer, other than skin cancer, within 5 years prior to enrollment.\n4. Pregnancy or nursing.\n5. Known systemic disease that predisposes to neuropathy.\n6. Other central nervous system diseases.",{"count":59,"type":22},39,"OBSERVATIONAL","The project aims to perform both conventional nerve-conduction studies and axonal-excitability assessments using the TRONDF protocol in patients with selected forms of Charcot-Marie-Tooth disease, with comparison to individuals affected by dysimmune, acquired neuropathies, specifically chronic inflammatory demyelinating polyneuropathy (CIDP) and anti-MAG-neuropathy. The study further includes the analysis of nerve fibers obtained from skin biopsy in patients with CMT, as well as ultrasound evaluation of nerves (from the wrist to the axilla) and of intrinsic hand muscles. Axonal-excitability techniques involve the delivery of two electrical stimuli to the nerve under investigation; both stimuli vary in intensity, whereas only the first, known as the conditioning stimulus, varies in duration. Changes in response amplitude are then measured as these stimulation parameters are systematically adjusted. Some preliminary studies have already suggested the effectiveness of this method in distinguishing CMT1A from certain forms of acquired demyelinating disease, including acute inflammatory demyelinating polyradiculoneuropathy (AIDP) and CIDP. Despite the promising results, only a limited number of studies have so far been conducted in humans and mice, and no comprehensive and systematic study has yet been carried out describing the changes in axonal excitability in the various CMT subtypes, either in humans or in mouse models.",[29,63,64,65,66],"CMT1A","Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Polyneuropathy Associated With Anti-MAG Antibodies (Anti-MAG Polyneuropathy)","Anti-MAG Neuropathy",[29,68,69,70,63,71,72,73,74,75,76,77,78],"Neurophysiology","Axonal excitability","Ultrasound (US)","CMT1B","CMTX1","CMT2I\u002FJ","CMT4B2","CMT4D","CMT4J","CIDP","anti-MAG","2026-03-06",{"date":81,"type":41},"2026-03-10",{"date":83,"type":41},"2025-03-03",{"date":85,"type":22},"2026-05",{"name":87,"class":48},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":96,"targetDuration":98,"studyType":60,"phases":4,"briefSummary":99,"conditions":100,"keywords":166,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":182},"100289408","the-myelin-disorders-biorepository-project-100289408","NCT03047369","The Myelin Disorders Biorepository Project","The Myelin Disorders Biorepository Project and Global Leukodystrophy Initiative Clinical Trials Network","MDBP","Inclusion Criteria (Affected Subjects):\n\n* Male or female of any age;\n* Suspected or confirmed diagnosis of leukodystrophy or other disorder affecting the white matter of the brain based primarily on the finding of central nervous system neuroimaging consistent with this diagnosis or on an existing diagnosis of a leukodystrophy or genetic leukoencephalopathy as defined in existing classification systems, or in the presence of variant(s) of uncertain significance or genotype consistent with leukodytrophy;\n* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent;\n* Willingness to provide clinical data, participate in standardized assessments, and\u002For provide biologic samples.\n\nExclusion Criteria (Affected Subjects)\n\n* Established diagnosis at the time of referral that is not consistent with a genetic disorder of the white matter, such as an acquired demyelinating condition (e.g. multiple sclerosis), or an infectious etiology, with the exception of sequelae of congenital infections such as CMV;\n* Inability to provide consent.\n\nInclusion Criteria (Healthy Controls)\n\n* Male or female of any age;\n* Individuals with no confirmed or suspected diagnosis of leukodystrophy or other disorder affecting the white matter of the brain (including affected patients' caregivers);\n* Documentation of informed consent by the subject, parent, or legal guardian, and, if appropriate, documentation of assent.\n\nExclusion Criteria (Healthy Controls)\n\n\\- Inability to provide consent.",{"count":97,"type":22},12000,"10 Years","The Myelin Disorders Biorepository Project (MDBP) seeks to collect and analyze clinical data and biological samples from leukodystrophy patients worldwide to support ongoing and future research projects. The MDBP is one of the world's largest leukodystrophy biorepositories, having enrolled nearly 2,000 affected individuals since it was launched over a decade ago.\n\nResearchers working in the biorepository hope to use these materials to uncover new genetic etiologies for various leukodystrophies, develop biomarkers for use in future clinical trials, and better understand the natural history of these disorders. The knowledge gained from these efforts may help improve the diagnostic tools and treatment options available to patients in the future.",[101,102,103,104,105,106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127,128,129,130,131,132,133,134,135,136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,152,29,153,154,155,156,157,158,159,160,161,162,163,164,165],"Leukodystrophy","White Matter Disease","Leukoencephalopathies","4H Syndrome","Adrenoleukodystrophy","AMN","ALD","ALD Gene Mutation","ALD (Adrenoleukodystrophy)","X-linked Adrenoleukodystrophy","X-ALD","Adrenomyeloneuropathy","Aicardi Goutieres Syndrome","AGS","Alexander Disease","Alexanders Leukodystrophy","AxD","ADLD","Canavan Disease","CTX","Cerebrotendinous Xanthomatoses","Krabbe Disease","GALC Deficiency","Globoid Leukodystrophy","TUBB4A-Related Leukodystrophy","H-ABC - Hypomyelination, Atrophy of Basal Ganglia and Cerebellum","HBSL","HBSL - Hypomyelination, Brain Stem, Spinal Cord, Leg Spasticity","LBSL","Leukoencephalopathy With Brain Stem and Spinal Cord Involvement and High Lactate Syndrome (Disorder)","Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation","ALSP","CSF1R Gene Mutation","HCC - Hypomyelination and Congenital Cataract","MLC1","Megalencephalic Leukoencephalopathy With Subcortical Cysts","MLD","Metachromatic Leukodystrophy","PMD","Pelizaeus-Merzbacher Disease","PLP1 Null Syndrome","PLP1 Gene Duplication | Blood or Tissue | Mutations","Pelizaeus Merzbacher Like Disease","Peroxisomal Biogenesis Disorder","Zellweger Syndrome","Refsum Disease","Salla Disease","Sialic Storage Disease","Sjögren","Sjogren-Larsson Syndrome","Van Der Knapp Disease","Vanishing White Matter Disease","CMT","Mct8 (Slc16A2)-Specific Thyroid Hormone Cell Transporter Deficiency","Allan-Herndon-Dudley Syndrome","Cadasil","Cockayne Syndrome","Multiple Sulfatase Deficiency","Gangliosidoses","GM2 Gangliosidosis","BPAN","Labrune Syndrome","LCC","Mucopolysaccharidoses","TBCK-Related Intellectual Disability Syndrome",[167,168,169,170,171,172],"leukodystrophy","white matter disease","leukoencephalopathy","myelin","demyelinating","mdbp","2025-10-22",{"date":175,"type":41},"2025-10-23",{"date":177,"type":41},"2016-12-08",{"date":179,"type":22},"2030-12-08",{"name":181,"class":48},"Children's Hospital of Philadelphia",23,{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":4,"eligibilityCriteria":189,"healthyVolunteers":16,"sex":17,"minAge":190,"maxAge":191,"enrollmentInfo":192,"targetDuration":4,"studyType":23,"phases":194,"briefSummary":195,"conditions":196,"keywords":4,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":211},"100514716","assessments-in-patients-with-muscular-pathology-and-in-control-subjects--the-actilige-next-study-100514716","NCT05982119","Assessments in Patients With Muscular Pathology and in Control Subjects : The ActiLiège Next Study","Gait Analysis Parameter, Stair Climbing and Upper Limb Evaluation in Patients With Muscular Pathology and in Control Subjects: The ActiLiège Next Study","Inclusion criteria\n\n* For the patients:\n\n  * Genetically confirmed diagnosis of DMD, FSHD, DM1, CMT or FKRP mutations or confirmed CNM based on muscle biopsy.\n  * FSHD, DM1, CMT and CNM patients should be ambulant or in transition.\n  * DM1 and CMT patients should present sensori-motor signs on physical examination.\n  * Under the age of 20 years for patients with DMD, CNM or between the ages of 5 and 80 years for patients with FSHD, CMT and DM1.\n  * More than 2 years old for patients with FKRP mutations\n  * Non-ambulant DMD patients must be able to remain seated in an arm- or a wheelchair for at least one hour.\n  * Patients with DMD treated with corticosteroids for at least 6 months or initiated corticosteroid at V0 (except for patients under 4).\n  * Signed informed consent form by patient himself or, in case of minor patients, signed informed consent form by patient's parents or legal guardians.\n* For the control subjects:\n\n  * Ambulant boys and girls under 20 years old\n  * Signed informed consent form by patient him\u002Fherself or, in case of minor patients, signed informed consent form by patient's parents or legal guardians.\n\nExclusion Criteria:\n\n* For the patients:\n\n  * Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed.\n  * Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs (for ambulant patients).\n  * A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion.\n  * Patients who are participating in an interventional clinical trial.\n  * DMD patients in transition who are not on corticosteroids.\n* For the control subjects:\n\n  * Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs.\n  * Elite athletes (at the national level).\n  * A chronic or acute muscular, neurological, infectious, or inflammatory pathology within the 3-week period immediately prior to inclusion.\n  * An orthopedic, neuromuscular, or neurological pathology that affects the quality of the subject's walking gait.","1 Year","80 Years",{"count":193,"type":22},300,[25],"The objective of the ActiLiège Next study is to collect longitudinal data from patients and control subjects using a wearable magneto-inertial device. By collecting natural history data in various neuromuscular disorders (Duchenne Muscular Dystrophy, Fascioscapulohumeral Muscular Dystrophy, Myotonic Dystrophy 1, Charcot-Marie-Tooth, Centronuclear Myopathy, Congenital Muscular Dystrophy), we aim to validate digital outcome measures to continuously assess motor function in real-life.",[197,198,199,29,200,201],"Duchenne Muscular Dystrophy","Fascioscapulohumeral Muscular Dystrophy","Myotonic Dystrophy 1","Centronuclear Myopathy","Congenital Muscular Dystrophy","2025-05-15",{"date":204,"type":41},"2025-05-20",{"date":206,"type":41},"2020-07-10",{"date":208,"type":22},"2026-03",{"name":210,"class":48},"Centre Hospitalier Universitaire de Liege",8,{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":222,"conditions":223,"keywords":231,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":49},"100519209","polyneuropathy-impairments-and-physical-activity---the-polyimpact-study-100519209","NCT06040567","Polyneuropathy, Impairments and Physical Activity - The PolyImPAct Study","PolyImPAct","Inclusion Criteria:\n\nInclusion Criteria patients:\n\n\\> 18 years Diagnosed with polyneuropathy (verified by nerve conduction)\n\nInclusion Criteria healthy controls:\n\n\\> 18 years Healthy\n\nExclusion Criteria:\n\nExclusion Criteria patients:\n\nNot verified polyneuropathy\n\nExclusion Criteria healthy controls:\n\nDiabetes, brain-, nerve-, muscle-, kidney-, or liver disease. Diagnosed with polyneuropathy","100 Years",{"count":221,"type":22},520,"The project aims to investigate the validity, and reliability of outcome measures of muscle strength, functioning (gait, balance, and fine motor skills), physical activity, and patient-reported outcome measures of functioning (gait, balance, and fine motor skills), and daily living among patients with polyneuropathy. Further, the project aims to compare physical activity and patient-reported outcome measures of functioning (gait, balance, and fine motor skills), and daily living among patients with polyneuropathy with physical activity and patient-reported outcome measures of functioning (gait, balance, and fine motor skills) and daily living in healthy adults.",[64,224,225,226,29,227,228,229,230],"Vasculitic Neuropathy","POEMS Syndrome","Multifocal Motor Neuropathy","hATTR Amyloidosis","Diabetic Polyneuropathy","Idiopathic Neuropathy","Polyneuropathies",[232,233,234,235,236,237,238,239],"Polyneuropathy","Clinical outcome measures","Patient reported outcome measures (PROMs)","Physical activity","Accelerometer","Validity","Reliability","Responsiveness","2025-04-03",{"date":242,"type":41},"2025-04-06",{"date":244,"type":41},"2023-09-23",{"date":246,"type":22},"2026-12-31",{"name":248,"class":48},"Rigshospitalet, Denmark",{"id":250,"slug":251,"hasResults":11,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":256,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":258,"conditions":259,"keywords":307,"overallStatus":37,"whyStopped":4,"lastUpdateSubmitDate":310,"lastUpdatePostDateStruct":311,"startDateStruct":313,"completionDateStruct":315,"leadSponsor":317,"locationsCount":49},"100508586","natural-history-study-for-charcot-marie-tooth-disease-100508586","NCT05902351","Natural History Study for Charcot Marie Tooth Disease","Global Registry for Inherited Neuropathies Natural History Study for Charcot Marie Tooth Disease","Inclusion Criteria:\n\nPatients will be made aware of the study by HNF and others (referenced above) and invited to participate. Once patients have reviewed and signed electronically the informed consent document, it is attached to their file.\n\nAll affected individuals with CMT\u002FIN are eligible to participate in GRIN with proper informed consent.\n\nChildren, adolescents and adults with either a confirmed diagnosis or suspected to have CMT\u002FIN are eligible with parent and\u002For guardian consent.\n\nIndividuals that have been clinically diagnosed through family history and\u002For standard clinical testing (e.g. neuro exam, EMG, NCS) and\u002For genetically tested or suspected to have CMT\u002FIN (note: many mutations have not been identified yet) are eligible.\n\nExclusion Criteria:\n\nPeople that do not have Charcot-Marie-Tooth or other Inherited Neuropathies",{"count":257,"type":22},10000,"The goal of this Natural History Study for Charcot-Marie-Tooth is to acquire, record, and analyze patient-reported data and associated genetic reports, Electronic Health Records (EHRs) and clinical notes to identify the burden, diagnostic journey, and prevalence of disease that will aid scientists in their work toward finding a cure.\n\nParticipants will be asked to complete a Natural History Survey.",[260,29,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,276,277,278,279,280,281,282,283,284,285,286,287,288,289,290,291,292,293,294,295,296,297,298,299,300,301,302,303,304,305,306],"Charcot-Marie-Tooth Disease","Charcot-Marie-Tooth Disease, Type IA","Charcot-Marie-Tooth Disease Type 2A","Charcot-Marie-Tooth Disease Type 2","Charcot-Marie-Tooth Disease, Type 2C","Charcot-Marie-Tooth Disease Type 2A2B","Charcot-Marie-Tooth Disease Type 2B2","Charcot-Marie-Tooth Disease Type 2A1","Charcot-Marie-Tooth Disease Type 4B1","Charcot-Marie-Tooth Disease, Type IB","Charcot-Marie-Tooth Disease Type 2B1","Charcot-Marie-Tooth Disease Type 2U (Diagnosis)","Charcot-Marie-Tooth Disease Type 4A","Charcot-Marie-Tooth Disease, Type 4A, Axonal Form","Charcot-Marie-Tooth Disease Type 2A2A","Charcot-Marie-Tooth Disease Type 2S (Disorder)","Charcot-Marie-Tooth Disease and Deafness","Charcot-Marie-Tooth Disease Type 4B2","Charcot-Marie-Tooth Disease Type 4H","Charcot-Marie-Tooth Disease Type 1F","Charcot-Marie-Tooth Disease Type 4C","Charcot-Marie-Tooth Disease Type 4E","Charcot-Marie-Tooth Disease Type 1D","Charcot-Marie-Tooth Disease Type 2Q (Diagnosis)","Charcot-Marie-Tooth Disease Type 2A2","Charcot-Marie-Tooth Disease Type 2N (Diagnosis)","Charcot-Marie-Tooth Disease Type 2B5","Charcot-Marie-Tooth Disease Type 2D","Charcot-Marie-Tooth Disease Type 4D","Charcot-Marie-Tooth Disease Type 2K","Charcot-Marie-Tooth Disease Type 2L (Diagnosis)","Charcot-Marie-Tooth Disease Type 2T","Charcot-Marie-Tooth Disease Type 2I","Charcot-Marie-Tooth Disease Type 2J","Charcot-Marie-Tooth Disease Type 2E","Charcot-Marie-Tooth Disease Type 2G","Charcot-Marie-Tooth Disease Type 1C","Charcot-Marie-Tooth Disease Type 2R","Charcot-Marie-Tooth Disease Type 2O (Diagnosis)","Charcot-Marie-Tooth Disease Type 2M","Charcot-Marie-Tooth Disease Type 2P","Charcot-Marie-Tooth Disease Type 2Y","Charcot-Marie-Tooth Disease Type 4F (Diagnosis)","Charcot-Marie-Tooth Disease Type 4B3","Charcot-Marie-Tooth Disease Type 2H","HNPP","X-Linked Charcot-Marie-Tooth Disease",[308,309,29,260,153],"Inherited Neuropathies","Peripheral Neuropathy","2024-09-30",{"date":312,"type":41},"2024-10-01",{"date":314,"type":41},"2013-11-01",{"date":316,"type":22},"2029-12-31",{"name":318,"class":319},"Hereditary Neuropathy Foundation","OTHER_GOV"]